Brokers Set Expectations for CRBP Q1 Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Corbus Pharmaceuticals in a research report issued to clients and investors on Thursday, November 7th. HC Wainwright analyst A. Maldonado anticipates that the biopharmaceutical company will earn ($1.33) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $80.00 price objective on the stock. The consensus estimate for Corbus Pharmaceuticals' current full-year earnings is ($3.80) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals' Q2 2025 earnings at ($1.40) EPS, Q3 2025 earnings at ($1.46) EPS and Q4 2025 earnings at ($1.54) EPS.

A number of other research analysts have also recently commented on the company. Mizuho reiterated an "outperform" rating and issued a $74.00 price objective on shares of Corbus Pharmaceuticals in a report on Friday, September 20th. StockNews.com cut Corbus Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, August 10th. Wedbush restated an "outperform" rating and issued a $51.00 price objective on shares of Corbus Pharmaceuticals in a report on Monday, November 4th. Lifesci Capital upgraded shares of Corbus Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, August 21st. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $82.00 price objective on shares of Corbus Pharmaceuticals in a research report on Friday, September 20th. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $65.86.

Corbus Pharmaceuticals Trading Down 2.9 %

Corbus Pharmaceuticals stock traded down $0.55 during midday trading on Monday, hitting $18.23. 107,628 shares of the stock were exchanged, compared to its average volume of 573,345. The stock has a market capitalization of $219.49 million, a price-to-earnings ratio of -3.97 and a beta of 2.56. The stock's 50-day simple moving average is $28.32 and its 200 day simple moving average is $41.93. Corbus Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $61.90.

Insider Transactions at Corbus Pharmaceuticals

In other Corbus Pharmaceuticals news, major shareholder Cormorant Asset Management, Lp acquired 350,000 shares of the stock in a transaction on Friday, September 20th. The shares were bought at an average cost of $20.01 per share, with a total value of $7,003,500.00. Following the transaction, the insider now owns 2,375,000 shares of the company's stock, valued at approximately $47,523,750. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 4.00% of the company's stock.

Institutional Trading of Corbus Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in CRBP. SG Americas Securities LLC purchased a new stake in shares of Corbus Pharmaceuticals in the 3rd quarter worth about $151,000. Victory Capital Management Inc. raised its position in Corbus Pharmaceuticals by 29.9% during the third quarter. Victory Capital Management Inc. now owns 24,760 shares of the biopharmaceutical company's stock worth $511,000 after acquiring an additional 5,700 shares during the last quarter. abrdn plc lifted its holdings in shares of Corbus Pharmaceuticals by 422.9% in the third quarter. abrdn plc now owns 26,894 shares of the biopharmaceutical company's stock valued at $555,000 after purchasing an additional 21,751 shares in the last quarter. Rhumbline Advisers acquired a new stake in shares of Corbus Pharmaceuticals in the second quarter valued at approximately $638,000. Finally, Acadian Asset Management LLC acquired a new position in shares of Corbus Pharmaceuticals during the 2nd quarter worth approximately $716,000. Institutional investors and hedge funds own 64.64% of the company's stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.